Clinicopathological indices to predict hepatocellular carcinoma molecular classification-Reference-Cited by-同舟云学术

Clinicopathological indices to predict hepatocellular carcinoma molecular classification

Published:2015-06-29 Issue:1 Volume:36 Page:108-118
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Tan Poh Seng¹²,Nakagawa Shigeki¹,Goossens Nicolas¹³,Venkatesh Anu¹,Huang Tiangui⁴,Ward Stephen C.⁴,Sun Xiaochen¹,Song Won-Min⁵,Koh Anna¹,Canasto-Chibuque Claudia¹,Deshmukh Manjeet¹,Nair Venugopalan⁶,Mahajan Milind⁵,Zhang Bin⁵,Fiel Maria Isabel⁴,Kobayashi Masahiro⁷,Kumada Hiromitsu⁷,Hoshida Yujin¹

Affiliation:

1. Division of Liver Diseases; Department of Medicine; Liver Cancer Program; Tisch Cancer Institute; Icahn School of Medicine at Mount Sinai; New York NY USA

2. Division of Gastroenterology and Hepatology; University Medicine Cluster; National University Health System; Singapore Singapore

3. Division of Gastroenterology and Hepatology; Geneva University Hospital; Switzerland

4. Department of Pathology; Icahn School of Medicine at Mount Sinai; New York NY USA

5. Department of Genetics and Genomic Sciences; Icahn School of Medicine at Mount Sinai; New York NY USA

6. Department of Neurology; Icahn School of Medicine at Mount Sinai; New York NY USA

7. Department of Hepatology; Toranomon Hospital; Tokyo Japan

Funder

Uehara Memorial Foundation

FLAGS foundation

Nuovo-Soldati Cancer Research Foundation

Hôpitaux Universitaires de Genève

National Institutes of Health

Irma T. Hirschl Trust

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12889/fullpdf

Reference59 articles.

1. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma;Hoshida;J Hepatol,2014

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

4. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design;Llovet;Clin Cancer Res,2014

5. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma;Hoshida;Cancer Res,2009

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC;Surgical Oncology;2024-08

2. The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma;Journal of Proteome Research;2024-07-09

3. Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection;European Radiology;2024-05-20

4. Primary liver cancer spectrum: current knowledge and the next steps;Hepatobiliary Surgery and Nutrition;2024-02

5. Transplantation Pathology;MacSween's Pathology of the Liver;2024